KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Short-term Investments (2017 - 2025)

Moderna (MRNA) has disclosed Short-term Investments for 9 consecutive years, with $3.2 billion as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 37.15% to $3.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, down 37.15% year-over-year, with the annual reading at $3.2 billion for FY2025, 37.15% down from the prior year.
  • Short-term Investments for Q4 2025 was $3.2 billion at Moderna, down from $3.4 billion in the prior quarter.
  • The five-year high for Short-term Investments was $6.7 billion in Q4 2022, with the low at $2.3 billion in Q1 2021.
  • Average Short-term Investments over 5 years is $4.6 billion, with a median of $4.8 billion recorded in 2022.
  • The sharpest move saw Short-term Investments soared 325093.8% in 2021, then plummeted 37.15% in 2025.
  • Over 5 years, Short-term Investments stood at $3.9 billion in 2021, then soared by 72.65% to $6.7 billion in 2022, then dropped by 14.93% to $5.7 billion in 2023, then fell by 10.51% to $5.1 billion in 2024, then plummeted by 37.15% to $3.2 billion in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $3.2 billion, $3.4 billion, and $3.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.